BioSpace News Archive

Definitive merger agreement with Forte Biosciences announced February 19, 2020

Acceleron Pharma Inc today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2019.

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), today announced financial results for the fourth quarter and full year 2019.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today reported full-year 2019 financial results.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced its fourth quarter and full year 2019 financial results and business highlights.

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin and wound conditions, is pleased to announce that it successfully closed on an asset purchase agreement for certain wound care, disinfection and animal health care products in the Middle East, Australia and Europe for $1.1 million with MicroSafe Group.

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, reported its financial and operational results for the third quarter of its fiscal year 2020, ending December 31, 2019.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ended December 31, 2019. “The Company closed 2019 on a strong, positive trajectory, and we look at the past year as one of

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will participate at the following upcoming investor conferences in March 2020 : The Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 . A corporate presentation is scheduled for 8:40 a.m. Eastern Time